DB22819InvestigationalVaccines
WGc-0201 is under investigation in clinical trial NCT07077369 (WGc-0201 Plus Tislelizumab in HCC With High Risk of Recurrence and Metastasis After Radical Therapy).
- Code names
- WGc-0201
What you can answer from here — as of February 06, 2026
Which companies are running trials of WGc-0201, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account